Surgery Doctors in Claremont, NH Accepting Medicare

3 Surgery doctors found. Showing 1 - 3

Dr. Ernest James Hanowell, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 243 Elm St, Valley Regional Surgical Associates, Claremont, NH 03743 Phone: 603-542-6777

Carl E Tetirick, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 251 Elm Street, Claremont, NH 03743 Phone: 603-542-6777    Fax: 603-542-6731

Volker Bradley, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 7 Dunning St, Claremont, NH 03743 Phone: 603-543-3501    Fax: 603-542-6486

News Archive

Half of six million major depressive disorder with comorbid panic attack cases go untreated

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the U.S., out of six million cases of major depressive disorder with comorbid panic attack, three million are untreated. Comorbid mental disorders are influential factors impacting the diagnosis and treatment of mental disorders.

People's propensity to contribute to public good increases if contributions made public: Research

Public disclosure of companies' pollution habits has been an effective method of reducing pollution in many countries. Similarly, research has shown that people's and firms' propensity to contribute to public good increases if their contributions are made public. Findings from the University of Gothenburg reveal that the expected positive effect of disclosure can sometimes be crowded out by other factors at play.

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.

Two recent experimental treatments improve visual function in mouse models of retinitis pigmentosa

Two recent experimental treatments - one involving skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy - have been shown to produce long-term improvement in visual function in mouse models of retinitis pigmentosa (RP), according to the Columbia University Medical Center (CUMC) scientists who led the studies. At present, there is no cure for RP, the most common form of inherited blindness.

Read more Medical News

› Verified 8 days ago